John Flaherty | Executive Director, Virology Clinical Development
Gilead Science

John Flaherty, Executive Director, Virology Clinical Development, Gilead Science

Dr Flaherty received his Doctor of Pharmacy degree from the University of Southern California, School of Pharmacy, after which he completed a clinical residency and Infectious Diseases fellowship at the University of California at San Francisco (UCSF). After serving as a clinical faculty member at the UCSF School of Pharmacy for over 13 years, Dr. Flaherty transitioned to a career in the pharmaceutical industry in 1998. Over the past 24 years he has held various positions of increasing responsibility within Medical Affairs and Clinical Research mostly at Gilead Sciences. Currently, he is Executive Director, Clinical Development, and oversees the viral hepatitis treatment programs in HBV, HCV, and HDV, including Development Lead for tenofovir alafenamide (Vemlidy) and bulevirtide (Hepcludex). Dr. Flaherty is an author of over 75 peer-reviewed journal articles, and has been the recipient of numerous awards and honors. In his spare time, he enjoys spending time with family, including his 3 grandchildren, and pursuing hobbies that include travel, surfing, and enjoying good food and fine wines.


WVIC/WAC Day 3 - Dec 1 @ 10:10

New and Emerging Strategies for the Treatment and Potential Cure of Hepatitis B Virus and Hepatitis D Virus Infections

last published: 01/Dec/22 17:25 GMT

back to speakers

For conference programme and speaking opportunities:
Lauren Sheppard

For sponsorship and exhibition opportunities:
Thomas Hall